US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

0.8402

+0.04025.03%

Post-market: 0.84920.0090+1.07%18:44 EDT

Volume:162.62K

Turnover:130.10K

Market Cap:38.22M

PE:-0.39

High:0.8402

Open:0.7956

Low:0.7542

Close:0.8000

Loading ...

Overview Company News Filings

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of Apx3330 in Diabetic Retinopathy

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)

Analysts’ Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)

Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Opus Genetics reinstated with a Buy at H.C. Wainwright

Opus Genetics Inc reports results for the quarter ended September 30 - Earnings Summary

Opus Genetics Q3 EPS $(0.29) Down From $0.25 YoY, Sales $3.87M Down From $11.94M YoY

Press Release: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)

Opus Genetics Inc : Jonestrading Cuts Target Price to $9 From $11

THOMSON REUTERS

Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview

Opus Genetics Inc : Alliance Global Partners Cuts Target Price to $15 From $20

THOMSON REUTERS

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IRD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":0.8402,"timestamp":1745611200000,"preClose":0.8,"halted":0,"volume":162623,"hourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"delay":0,"floatShares":36127791,"shares":45483823,"eps":-2.153504,"marketStatus":"Market Closed","change":0.0402,"latestTime":"04-25 16:00:00 EDT","open":0.7956,"high":0.8402,"low":0.7542,"amount":130101.92891909998,"amplitude":0.1075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.153504,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.8,"latestTime":"08:57 EDT","volume":123,"amount":98.4599994,"timestamp":1745585844295},"postHourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"volumeRatio":1.143454403133233,"impliedVol":2.1502,"impliedVolPercentile":0.544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":36127791,"roa":"-46.90%","roe":"-152.46%","lyrEps":-2.153504,"volumeRatio":1.143454403133233,"shares":45483823,"dividePrice":0,"high":0.8402,"amplitude":0.1075,"preClose":0.8,"low":0.7542,"week52Low":0.65,"pbRate":"5.68","psRate":"3.48","week52High":2.18,"institutionHeld":0,"latestPrice":0.8402,"eps":-2.153504,"divideRate":0,"volume":162623,"delay":0,"ttmEps":-2.153504,"open":0.7956,"prevYearClose":1.19,"prevWeekClose":0.7599,"prevMonthClose":0.9818,"prevQuarterClose":0.9818,"fiveDayClose":0.7599,"twentyDayClose":0.9903,"sixtyDayClose":1.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492127675","title":"Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for    Phase 3 Trial of Apx3330 in Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127675?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA5Z4MXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2491179579","title":"Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491179579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491179579?lang=en_us&edition=fundamental","pubTime":"2024-12-15 23:50","pubTimestamp":1734277821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and Brainstorm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BCLI","IRD","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2491157917","title":"Analysts’ Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491157917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491157917?lang=en_us&edition=fundamental","pubTime":"2024-12-15 23:40","pubTimestamp":1734277246,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Elevation Onc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-opus-genetics-ird-elevation-oncology-elev?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-opus-genetics-ird-elevation-oncology-elev?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4137","HCSG","IRD","BK4539","ELEV","BK4139"],"gpt_icon":0},{"id":"2490280167","title":"Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490280167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490280167?lang=en_us&edition=fundamental","pubTime":"2024-12-12 19:39","pubTimestamp":1734003540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 06:39 ET (11:39 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2488147799","title":"Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488147799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488147799?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:00","pubTimestamp":1733230800,"startTime":"0","endTime":"0","summary":"6-month efficacy and safety data from ongoing Phase 1/2 trial of OPGx-LCA5 to be presentedFARMINGTON HILLS, Mich., Dec.  03, 2024  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990534/0/en/Opus-Genetics-to-Host-Virtual-KOL-Event-on-OPGx-LCA5-as-a-Treatment-for-LCA5-Associated-Inherited-Retinal-Disease-on-December-11-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","BK4588","BK4585","BK4218","BK4181","HST","LCA","BK4007","IRD"],"gpt_icon":0},{"id":"2483753138","title":"Opus Genetics reinstated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2483753138","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483753138?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:40","pubTimestamp":1731584442,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reinstated coverage of Opus Genetics  with a Buy rating and $8 price target The firm believes inherited retinal disease development presents an efficient path to concise studies offering insight into gene therapy efficacy. The firm believes the company’s 2025 catalysts can give the its platform the appropriate foundation for continued innovation and development over the near-term.OCUP Earnings this Week: How Will it Perform?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/opus-genetics-reinstated-buy-h-114042242.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-reinstated-buy-h-114042242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2482084734","title":"Opus Genetics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482084734","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482084734?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:32","pubTimestamp":1731425575,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc reports results for the quarter ended September 30 - Earnings SummaryOpus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 29 cents per share for the quarter ended September","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ26U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2482701746","title":"Opus Genetics Q3 EPS $(0.29) Down From $0.25 YoY, Sales $3.87M Down From $11.94M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2482701746","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482701746?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:18","pubTimestamp":1731417530,"startTime":"0","endTime":"0","summary":"Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.29) per share. This is a 216 percent decrease over earnings of $0.25 per share from the same period last year.  The company reported $3.87 million in sales this","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41899449/opus-genetics-q3-eps-0-29-down-from-0-25-yoy-sales-3-87m-down-from-11-94m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Opus Genetics Q3 EPS $(0.29) Down From $0.25 YoY, Sales $3.87M Down From $11.94M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2482709190","title":"Press Release: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482709190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482709190?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:59","pubTimestamp":1731416340,"startTime":"0","endTime":"0","summary":"FARMINGTON HILLS, Mich., Nov. 12, 2024  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases  and therapies to treat patients with other ophthalmological disorders , today announced that the independent members of its Board of Directors approved an equity award under the Company's 2021 Inducement Plan, as amended, as a material inducement to Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, in connection with his employment with the Company, effective November 7, 2024. The equity award was approved in accordance with Nasdaq Listing Rule 5635, which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IRD",".IXIC","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","BK4112","NQmain","BK4588"],"gpt_icon":0},{"id":"2482373988","title":"Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482373988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482373988?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:20","pubTimestamp":1731338459,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ultragenyx-pharmaceutical-rare-and-opus-genetics-ird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ultragenyx-pharmaceutical-rare-and-opus-genetics-ird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RARE","BK4137","BK4139","IRD","HCSG"],"gpt_icon":0},{"id":"2482582733","title":"Opus Genetics Inc : Jonestrading Cuts Target Price to $9 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2482582733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482582733?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:52","pubTimestamp":1731336752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nFWN3MI2CY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2482486421","title":"Opus Genetics Inc    expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482486421","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482486421?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:14","pubTimestamp":1731082460,"startTime":"0","endTime":"0","summary":"* Opus Genetics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 11 (estimated) for the period ending September 30 2024   * The Farmington Hills Michigan-ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Opus Genetics Inc    expected to post a loss of 25 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2479205640","title":"Opus Genetics Inc : Alliance Global Partners Cuts Target Price to $15 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2479205640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479205640?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:40","pubTimestamp":1730288435,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M60OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2478953586","title":"The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2478953586","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478953586?lang=en_us&edition=fundamental","pubTime":"2024-10-26 00:00","pubTimestamp":1729872000,"startTime":"0","endTime":"0","summary":"The resulting company will operate under the name Opus Geneticsand the Nasdaq ticker symbol . The acquisition of Opus by Ocuphire is a key milestone as it represents the first RD Fund portfolio company to enter the public markets. The milestone further validates the venture philanthropy model of derisking assets - making them more attractive to institutional investors and the public markets. \"That a highly skilled and experienced team - including former Opus executives and directors Ben Yerxa, Jean Bennett, and Adrienne Graves - will advance the Opus portfolio with a commitment to being a leader in developing genetic medicines for the treatment of IRDs accelerated our approval of the transaction,\" said Kelley.About the RD FundThe RD Fund , the venture investment arm of the Foundation Fighting Blindness, has a dual mission: accelerate the approval of therapies for retinal diseases and provide alternative revenue sources to further the Foundation's mission. Established in 2018, the RD Fu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/60vdFU.rAiuA7kZyFN2B7w--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5cb168ebae3b3e53c388d87fbdec28a8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/60vdFU.rAiuA7kZyFN2B7w--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5cb168ebae3b3e53c388d87fbdec28a8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rd-fund-announces-ocuphire-pharmas-160000785.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rd-fund-announces-ocuphire-pharmas-160000785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OCUP","BK4007","IRD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2024-05-10","symbol":"IRD","fiscalQuarterEnding":"2024/03","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-03-08","symbol":"IRD","fiscalQuarterEnding":"2023/12","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1709874000000,"reportTimeType":"pre","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-04-25","current":-0.632466,"percent":0.92562,"low":-2.964142,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"high":-0.560128,"avg":-1.33286,"sd":0.500679,"marketCap":36387058},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058}],"updateTime":1745785391293}}}